Do not initiate in rapidly or acutely deteriorating COPD or asthma. Not for use with other long-acting β 2-agonists. Do not exceed recommended dose. Prescribe a short-acting, inhaled β 2-agonist ...

which showed Trelegy was better than GSK’s already approved combinations Relvar/Breo Ellipta and Anoro Ellipta. Trelegy is also indicated to reduce exacerbations of COPD in patients with a ...